| Initial public offering of up to [*] equity shares of face value of Rs. 2/- each ("Equity Shares") of Veeda Clinical Research Limited ("the Company" or the "Company" or the "Issuer") for cash at a price of Rs. [*] per equity share (including a Share Premium of Rs. [*] per Equity Share) ("Offer Price") aggregating up to Rs. [*] crores ("Offer") comprising a fresh issue of [*] equity shares of face value of Rs. 2/- each aggregating up to
Rs. 185.00 crores ("Fresh Issue") and an offer for sale of up to 13,008,128 equity shares of face value of Rs. 2/- each ("Offered Shares") aggregating up to Rs. [*] crores, comprising an offer for sale of up to 3,493,895 equity shares of face value of Rs. 2/- each aggregating up to Rs. [*] crores by Basil Private Limited ("Promoter Selling Shareholder") and up to 9,514,233 equity shares of face value of Rs. 2/- each aggregating up to Rs. [*] crores by the other selling shareholders (as Defined Hereinafter and Together with the Promoter Selling Shareholder, the "Selling Shareholders" and such offer by the selling shareholders, the "Offer for Sale"). The offer shall constitute [*] % of the post-offer paid-up equity share capital of the company.
The company, in consultation with the brlms, may consider an issue of specified securities as may be permitted under the applicable law aggregating up to Rs. 37.00 crores prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by its company.
The face value of the equity shares is Rs. 2/- each. The offer price is [*] times the face value of the equity shares of Rs. 2/- each.
The price band and the minimum bid lot will be decided by the company.
|